publication date: Oct. 13, 2017

NIH announces immunotherapy consortium with 11 companies to support Cancer Moonshot goals

By Matthew Bin Han Ong

As part of NCI’s ongoing Cancer Moonshot program, the institute, NIH and 11 biopharmaceutical companies launched a five-year public-private research collaboration Oct. 12 designed to advance new immunotherapy treatments.

The $215 million consortium, the Partnership for Accelerating Cancer Therapies, will be managed by the Foundation for the National Institutes of Health. Initially, PACT will focus on efforts to identify, develop, and validate robust biomarkers that show promise in the clinic.

“We know today’s announcement is part of an effort that President Trump is deeply devoted to—advancing lifesaving cures for deadly diseases,” Eric Hargan, the newly appointed acting secretary of the Department of Health and Human Services, said at the rollout at the National Press Club. “It’s a special honor to be here in my first public appearance as acting secretary, because the HHS’s role in advancing medical research is a cherished important part of the nation, and today is a major step forward.”

This is likely the first time the current administration has issued a public endorsement of the Beau Biden Cancer Moonshot, an Obama-era White House initiative led by former Vice President Joe Biden that culminated in the formation of the FDA Oncology Center of Excellence and authorization of $1.8 million in new funding over seven years for cancer research via the 21st Century Cures Act.

PACT is modeled after another five-year consortium, the Accelerating Medicines Partnership, which was established in 2014 between NIH, FDA, and 10 industry partners to identify and validate promising biological targets for therapeutics.

“NIH does the basic scientific research, like identifying which biomarkers make … Continue reading NIH announces immunotherapy consortium with 11 companies to support Cancer Moonshot goals

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.